Avantor Investor Conference Presentation Deck
Avantor growth fueled by strong biopharma
industry fundamentals...
RICH FUNDING
ENVIRONMENT
Total worldwide venture funding
raised by biotech companies¹,
USD, Bn
+19%
19.4
2017
Navantor™
39.2
2021
Est. worldwide biopharma drug revenue²,
USD, Bn
mAbs 1
Cell Therapy & 2
Viral Vector 32
DNA/RNA
ROBUST PIPELINES
& OUTLOOK
Other
3
19
35
62
256
2020
414
2025 %
1. BCIQ (Oct 2021) with updated figures for 2021 as of 12/29/21. Includes seed funding, series A-E and higher, debt,
non-disclosed, general venture funding.
2. Includes traditional mAbs, recombinants and other protein-based therapeutics; Evaluate Pharma (Dec. 2021)
3. FDA, Nephron Research as of 11/30/21
10%
69%
42%
12%
CAGR
INCREASING
COMMERCIALIZATION
FDA new molecular
entity approvals³
Biologics
License
Applications
New Drug
Applications
310
136
2
174
2012-16
442
190
3
252
2017-21
40th Annual J.P. Morgan Healthcare Conference
4
11View entire presentation